Clinical Trial Update: Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients

View source ↗

Summary

The trial update examines circulating tumor DNA as a biomarker to predict relapse and overall survival in non-Hodgkin lymphoma patients, including diffuse large…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Peripheral T-cell Lymphoma

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Diffuse Large B Cell Lymphoma, Peripheral T Cell Lymphoma | Status: UNKNOWN